Meropenem Venus Pharma (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan cross‑linking. This inhibition compromises cell‑wall integrity, leading to osmotic lysis and bacterial death across a broad range of Gram‑negative, Gram‑positive and anaerobic pathogens.

The prescribed dose of Meropenem Venus Pharma is determined by the treating physician based on the type and severity of infection, the susceptibility of the causative organism, the patient’s renal function, age, weight and any concomitant conditions that may affect drug clearance.

Safety data for meropenem in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Meropenem Venus Pharma product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Meropenem shares a similar broad‑spectrum profile with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers enhanced stability against many β‑lactamases and a slightly broader Gram‑negative coverage. Compared with non‑carbapenem agents, it is often reserved for multidrug‑resistant infections where first‑line therapies have failed.

Meropenem Venus Pharma should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. The product must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept under controlled temperature conditions.

The sterile powder is reconstituted with a suitable diluent to form a solution for intravenous infusion. Administration is typically via a controlled IV infusion over 15‑30 minutes, with dosing intervals and duration determined by the prescribing clinician based on infection severity and patient factors.

Serious adverse events include the potential for seizures, especially in patients with renal impairment or pre‑existing CNS disorders; Clostridioides difficile‑associated colitis; severe hypersensitivity reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis; and renal toxicity in susceptible individuals.

Meropenem is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also required for individuals with severe renal impairment who have not had dose adjustments, and for patients with a history of seizures or central nervous system disorders.